BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding...

Area of Science:

• Oncology
• Regenerative Medicine
• Biotechnology

Background:

• Cancer treatment requires timely therapeutic decisions due to tumor heterogeneity and mutation-driven unpredictability.
• Current organoid technologies are primarily research-focused, lacking clinical applicability and rapid generation for personalized treatment selection.
• The time-consuming nature of traditional trial-and-error treatment strategies poses a significant challenge for cancer patients.

Purpose of the Study:

• To develop a novel, time-saving method for generating patient-specific organoids (PSO) for rapid clinical application.
• To enable swift selection of effective cancer therapies through in vitro drug sensitivity testing using PSO.
• To bridge the gap between research-driven organoid models and the clinical need for personalized cancer treatment.

Main Methods:

• Patient-specific organoids (PSO) were generated by dissolving the mesenchyme within tumor tissues.
• The developed organoid technology enables the creation of PSO from patient tumor samples within a single day.
• PSO were utilized for in vitro drug sensitivity assays and immune cell therapy efficacy assessment.

Main Results:

• The generated PSO accurately reflect the properties of the original in vivo tumor tissue.
• PSO facilitate in vitro drug sensitivity testing, identifying optimal clinical treatments for individual cancer patients.
• PSO show potential in evaluating the efficacy of immune cell-based cancer therapies.

Conclusions:

• The rapid generation of patient-specific organoids (PSO) offers a clinically relevant and time-efficient solution for personalized cancer therapy selection.
• PSO represent a significant advancement over research-oriented organoid models, providing direct clinical utility.
• This technology addresses the critical need for accelerated personalized medicine in cancer treatment.